entertainment -WSS

entertainment

author：comprehensive 2025-09-28 21:07:26 - browse：7628

FDA's Peter Marks talks with STAT's Adam Feuerstein — Peter Marks, the FDA's top regulator of gene therapies (right), speaks with STAT's Adam Feuerstein in San Francisco. Sarah Gonzalez/Peopletography for STAT

SAN FRANCISCO — Peter Marks, the Food and Drug Administration’s top regulator of gene therapies, seems very comfortable with granting some form of full approval to Elevidys, the Sarepta Therapeutics gene therapy for Duchenne muscular dystrophy, based on his comments to me on Monday night during our “fireside chat” at a STAT event.

To be clear, Marks declined to comment specifically about the ongoing FDA review of Elevidys. I tried. However, Marks described a “hypothetical case” in the context of my Sarepta questions that clearly suggested the failure of an Elevidys confirmatory study in October didn’t bother him all that much.

“Hypothetically, if you had a product that used an aggregate scale and all of the components of that aggregate scale looked pretty good, or nearly all of them look pretty good, but the aggregate, for various reasons, didn’t come out perfectly. We approved products based on that,” Marks told me.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Jerome Adams on the need for new antivirals for Covid
Next article： Heart attack and stroke risk calculators need revising

WSS

Activists slam private health insurers over coverage restrictions

Walensky prepares to leave CDC — and Congress — behind

Archived: an online chat discussing Ebola, vaccines, and a new epidemic

What affirmative action's end means to a medical student

The cancer drug shortage isn’t new — and neither are the solutions

DIEP, the 'gold standard' of breast reconstruction, is under threat

hotspot

entertainment

knowledge

Medicare proposal to cover medical devices draws a mixed reaction

Correcting Robert F. Kennedy Jr.'s vaccine 'facts'

Medical records are filled with copy

Penis shrinkage, a side effect of prostate cancer surgery, is temporary

Peter Hotez and the public health issue of online harassment

Trump’s hydroxychloroquine hype: a risk to my treatment and to him

In age of alternative facts, a scholarly course on calling out crap

BioMarin wins approval for gene therapy to treat hemophilia A

Jerome Adams on the need for new antivirals for Covid

Trump’s hydroxychloroquine hype: a risk to my treatment and to him

focus

AstraZeneca lung cancer study comes in below expectations

Being 'nonadherent' patient made me a more empathetic doctor

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

What affirmative action's end means to a medical student

Medicare proposal to cover medical devices draws a mixed reaction

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

knowledge

knowledge

hotspot

leisure time